A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

Exclusion Criteria

• •Allergy or hypersensitivity to the azole drugs.
• •Female subjects who are pregnant or lactating.
• •Patients who received more than four days of antifungal drugs to treat the current episode of invasive aspergillosis or rare mold infection.
• •Received within 24 hours prior to enrollment drugs that may cause QT interval prolongation.
• •Significant liver, kidney or heart dysfunction.
• •Not expected to survive for at least 5 days.